摘要
背景与目的间变淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因的发现促进了非小细胞肺癌(non-small cell lung cancer,NSCLC)分子靶向药物的发展,是继表皮生长因子受体之后NSCLC中重要的治疗靶点。本研究将探索克唑替尼治疗ALK阳性中晚期NSCLC患者的临床疗效。方法将28例ALK阳性中晚期NSCLC患者随机分为克唑替尼组(n=14)和化疗组(n=14),克唑替尼组给予克唑替尼胶囊250mg/粒,一次1粒,每日2次;化疗组给予多西他赛75 mg/m2静脉滴注1 h,每3周1次,3周为1个疗程,至少用药3个疗程,随访12个月,观察两组的临床疗效。结果克唑替尼组患者有效率为64.29%,明显高于化疗组的21.43%(P=0.026);克唑替尼组稳定率为85.71%,明显高于化疗组的40.86%(χ2=5.600,P=0.018);克唑替尼组患者中位无进展生存时间(progression free survival,PFS)为7.0个月,较化疗组患者中位PFS为4.0个月长(P=0.002)。结论克唑替尼在ALK阳性中晚期NSCLC患者的临床疗效优于常规化疗,可延长中位PFS,提高患者生存质量。
Background and objective The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase （ALK） positive non-small cell lung cancer. Methods Twenty-eight patients with advanced nonsmall cell lung cancer habouring ALK positive were randomly divided into crizotinib group （n=14） and chemotherapy group （n=14）. Patients in the crizotinib group were receive oral treatment with crizotinib （250 mg） twice daily. Patients in the che- motherapy group were administrated docetaxel injection （75 mg/m2） every three weeks and every patient was treated at least 3 period. Then clinical efficacy was observed after 12 mo followed-up. Results Effective rate of patients in the crizotinib group was 64.29%. It was significantly higher than that of the chemotherapy group （21.43%）（P=0.026）. The stable rate of patients in the crizotinib group was 85.71%. It was significantly higher than that of the chemotherapy group 40.86% （x2=5.600, P=0.018 ）. Median progression fxee survival （PFS） of the crizotinib group was 7.0 mo. It was longer than that of the chemotherapy group （4.0 too） （P=0.002）. Conclusion Crizotinib is superior to standard chemotherapy in patients with previously treated, ad- vanced ALK positive non-small cell lung cancer. The median PFS of patients is shorter. It can improve the quality of life about patients.
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2015年第10期616-620,共5页
Chinese Journal of Lung Cancer
基金
国家自然科学基金项目(No.81372827)资助~~
